Q-omics provides the consensus-scored CCDC69 profile across patient tissues and cancer cell-line models. CCDC69 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CCDC69 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, CCDC69 RNA expression shows 25,450 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, BLCA, and LSCC as cancer lineages where CCDC69 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC69 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC69 survival associations across molecular data types. CCDC69 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC69 RNA expression–survival associations across cancer types. High CCDC69 expression shows unfavorable associations in LUSC, but favorable associations in SKCM, KIRC, HNSC, BRCA and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CCDC69 RNA expression.
This table summarizes CCDC69 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC69. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC69 shows lower tumor expression in BLCA, COAD, LUAD, KIRP, LUSC and HNSC. The BLCA box plot shows higher CCDC69 RNA expression in normal versus tumor tissue (log2 FC = −3.944, t-test p < 0.001).
This table shows molecular features associated with CCDC69 in patient tissues and cancer cell lines. In patient samples, CCDC69 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC69 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
